Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lifecore BiomedicalLFCR -1.14%51 Cash Ratio is 1.01 as of Mar. 2026, which is 1343% above its 10-year median of 0.07. GuruFocus rates LFCR with a GF Score™ of 51/100 and a GF Value™ of $6.46 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 975 Drug Manufacturers companies, Lifecore Biomedical ranks better than 61.85% on this metric.
Lifecore Biomedical has a Cash Ratio of 1.01. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Lifecore Biomedical's Cash Ratio or its related term are showing as below:
LFCR'
s Cash Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.07 Max: 1.01
Current: 1.01
During the past 13 years, Lifecore Biomedical's highest Cash Ratio was 1.01. The lowest was 0.01. And the median was 0.07.
LFCR's Cash Ratio is ranked better than 61.85% of 975
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs LFCR: 1.01
Lifecore Biomedical (NAS:LFCR) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Lifecore Biomedical Cash Ratio Related Terms
Lifecore Biomedical Cash Ratio Historical Data
* Premium members only.
The historical data trend for Lifecore Biomedical's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lifecore Biomedical Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Lifecore Biomedical's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lifecore Biomedical (LFCR) has a Cash Ratio of 1.01 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Lifecore Biomedical and its competitors. This is 1343% above median its historical median of 0.07. Over the past decade, Lifecore Biomedical's Cash Ratio has ranged from 0.01 to 1.01. According to the industry distribution chart, Lifecore Biomedical ranks #372 out of 975 companies in the Drug Manufacturers industry, placing it in the top 38.2%.
Is Lifecore Biomedical's Cash Ratio too high?
Lifecore Biomedical's current Cash Ratio of 1.01 is 1343% above median its 10-year median of 0.07. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 1.01. The Drug Manufacturers industry median Cash Ratio is 0.61. Lifecore Biomedical's value of 1.01 is 65.6% above this industry median. Based on the distribution chart, Lifecore Biomedical ranks #372 out of 975 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Lifecore Biomedical has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lifecore Biomedical's Cash Ratio compare to DERM and ADCT?
According to the Drug Manufacturers industry distribution chart, Lifecore Biomedical ranks #372 out of 975 companies for Cash Ratio. This puts Lifecore Biomedical in the upper half of its industry. The industry median Cash Ratio is 0.61. Lifecore Biomedical's value of 1.01 is 65.6% above this benchmark. Historically, Lifecore Biomedical's own Cash Ratio has ranged from 0.01 to 1.01 over the past decade. While the company's 10-year median is 0.07 vs. the industry median of 0.61, Lifecore Biomedical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.61, based on 975 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lifecore Biomedical's current Cash Ratio of 1.01 is 65.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Lifecore Biomedical and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lifecore Biomedical's current Cash Ratio is 1.01, which is 1343% above median its own 10-year median of 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecore Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lifecore Biomedical (LFCR) is currently considered Possible Value Trap. The stock's GF Value™ is $6.46, compared to a current price of $4.32 — trading 33.1% below its estimated fair value. The current Cash Ratio is 1.01, which is 1343% above median its 10-year median of 0.07 and 65.6% above the Drug Manufacturers industry median of 0.61. Lifecore Biomedical's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Lifecore Biomedical (LFCR), the current Cash Ratio is 1.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lifecore Biomedical (LFCR) Overvalued in 2026?
Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued.
The current stock price of $4.32 is trading 33.1% below its estimated GF Value™ of $6.46.
GuruFocus considers Lifecore Biomedical to be Possible Value Trap.
Key valuation signals for LFCR:
Cash Ratio: 1.01 (1343% above median its 10-year median of 0.07)
GF Value™: $6.46 vs. price of $4.32 (33.1% below fair value)
Industry Position: 65.6% above the Drug Manufacturers median (#372 of 975)
No single metric tells the full story. See the LFCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
51GF Score
Get the complete analysis for LFCR
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFCR has been successfully added to your 
